Switzerland's Actelion yesterday saw its shares plunge 16.2% to 45.90 Swiss francs, its lowest level for four years, after the company announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of its lead product bosentan (sold as Tracleer) in patients suffering from idiopathic pulmonary fibrosis (IPF). While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was not met (p=0.21). However, the company noted, the well characterized safety profile of bosentan was confirmed.
Jean-Paul Clozel, chief executive of Actelion, Europe's largest biotechnology company, commented: "We are naturally disappointed with this outcome. While in BUILD-3 there is a consistent trend in favor of bosentan, these findings do not support initiating regulatory proceedings."
Notwithstanding, a company spokesman stated that the news does not change the Actelion's financial targets for 2010 for sales growth of more than 10% and cash earnings before interest and taxes rising nearly 20%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze